Global PD-1 and PD-L1 Inhibitors Market: Size, Trends and Forecasts (2018-2022)

Publisher Name :
Date: 01-Aug-2018
No. of pages: 101

Scope of the Report

The report titled “Global PD-1 and PD-L1 Inhibitors Market: Size, Trends and Forecasts (2018-2022)”, provides an in depth analysis of the global PD-1 and PD-L1 inhibitors market by value, by cancer, by treatment, by region, etc. The report also provides a detailed analysis of the China PD-1 and PD-L1 inhibitors market by value, by treatment and by cancer.

The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global PD-1 and PD-L1 Inhibitors market has also been forecasted for the period 2018-2022, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

The global PD-1 and PD-L1 inhibitors market is generally dominated. Many competitors have established worldwide reputation with the multinational patients while some provide their drugs to the domestic patients. The manufacturers of the PD-1 and PD-1 inhibitors market produce different type of drugs, some manufacturers produce PD-1 inhibitors, some produce PD-L1 inhibitors while other produce combination of PD-1 and PD-L1 inhibitors.

However, the competition in the global PD-1 and PD-L1 inhibitors market is dominated by few PD-1 and PD-L1 inhibitors manufacturers. Further, key players of the PD-1 and PD-L1 inhibitors market are Bristol-Myers Squibb, Merck & Co., Inc., Roche, AstraZeneca, Jiangsu Hengrui Medicine Co. Ltd. and BeiGene, Ltd. are also profiled with their financial information and respective business strategies.

Country Coverage


  • China

  • The US

  • ROW


Company Coverage


  • Bristol-Myers Squibb

  • Merck & Co., Inc.

  • Roche

  • AstraZeneca

  • Jiangsu Hengrui Medicine Co. Ltd.

  • BeiGene, Ltd.


Executive Summary

Cancer is the fastest growing disease across the world and one of the most important development in the field of cancer treatment is the introduction of immune checkpoint inhibitors-agents that help to stimulate the immune system. The two main cancer treatment approaches are: Programmed Death-1 (PD-1) and Programmed Death Ligand-1 (PD-L1) inhibitors. PD-1 and PD-L1 inhibitors are both found on the surface of the cancer cells and used to kill cancer cells.

The drugs approved as a PD-1 inhibitor are Pembrolizumab and Nivolumab and the drugs approved as a PD-L1 inhibitors are atezolizumab, Durvalumab and Avelumab. There are various PD-1 and PD-L1 inhibitors which are still in experimental phase of development. The adverse effects of PD-1 and PD-L1 inhibitors are pneumonitis, colitis, skin reactions, immune thrombocytopenia, cardiac insufficiency, diarrhea, pruritus, myocarditis and pneumonitis. PD-1 and PD-L1 inhibitors has a long history with continuously evolving new generation PD-1 and PD-L1 inhibitors. The PD-1 and PD-L1 inhibitors market can be segmented on the basis of type, indications, drug and distribution channel.

The global PD-1 and PD-L1 inhibitors market has increased at a significant annual growth rate during the years 2016-2017 and projections are made that the market would rise in the next four years i.e. 2018-2022 tremendously. The PD-1 and PD-L1 inhibitors market is expected to increase due to aging population, growth in GNI per capita, growing urban population, increasing incidence of certain types of cancer, rise in the number of people with cancer, etc. Yet the market faces some challenges such as high cost of oncology treatment, side effects and toxicity, failure of clinical trials, time consuming and uncertain regulatory process, etc.

Global PD-1 and PD-L1 Inhibitors Market: Size, Trends and Forecasts (2018-2022)

Table of Contents

1. Executive Summary

2. Introduction
2.1 PD-1 and PD-L1 Inhibitors: An Overview
2.1.1 PD-1 and PD-L1 Inhibitors Discovery Timeline
2.1.2 PD-1/PD-L1 Inhibitors Mechanism Action and Applications
2.1.3 PD-1/PD-L1 Inhibitors in Experimental Phase of Development
2.1.4 Adverse Effects of PD-1 and PD-L1 Inhibitors
2.2 PD-1 and PD-L1 Inhibitors Segmentation: An Overview
2.2.1 PD-1 and PD-L1 Inhibitors by Type
2.2.2 PD-1 and PD-L1 Inhibitors by Indications
2.2.3 PD-1 and PD-L1 Inhibitors by Drug
2.2.4 PD-1 and PD-L1 Inhibitors by Distribution Channel

3. Global Market Analysis
3.1 Global PD-1 and PD-L1 Inhibitors Market: An Analysis
3.1.1 Global PD-1 and PD-L1 Inhibitors Market by Value
3.1.2 Global PD-1 and PD-L1 Inhibitors Market by Segments (Metastatic PD-1 and PD-L1 Inhibitors and Adjuvant PD-1 and PD-L1 Inhibitors)
3.1.3 Global PD-1 and PD-L1 Inhibitors Market by Region (The US, China and ROW)
3.2 Global PD-1 and PD-L1 Inhibitors Market: Segment Analysis
3.2.1 Global Metastatic PD-1 and PD-L1 Inhibitors Market by Value
3.2.2 Global Adjuvant PD-1 and PD-L1 Inhibitors Market by Value

4. Regional Market Analysis
4.1 China PD-1 and PD-L1 Inhibitors Market: An Analysis
4.1.1 China PD-1 and PD-L1 Inhibitors Market by Value
4.1.2 China PD-1 and PD-L1 Inhibitors Market by Cancer (Non-small Cell Lung Carcinoma, Hepatocellular Carcinoma, Gastric Cancer, Esophageal Cancer, Small Cell Lung Cancer and Others)
4.1.3 China PD-1 and PD-L1 Inhibitors Market by Treatment (1L Treatment and 2L+ Treatment)
4.2 China PD-1 and PD-L1 Inhibitors Market: Treatment Analysis
4.2.1 China 1L PD-1 and PD-L1 Inhibitors Market by Value
4.2.2 China 1L PD-1 and PD-L1 Inhibitors Market by Cancer (Non-small Cell Lung Carcinoma, Hepatocellular Carcinoma, Gastric Cancer, Esophageal Cancer, Small Cell Lung Cancer and Others)
4.2.3 China 2L+ PD-1 and PD-L1 Inhibitors Market by Value
4.2.4 China 2L+ PD-1 and PD-L1 Inhibitors Market by Cancer (Non-small Cell Lung Carcinoma, Hepatocellular Carcinoma, Gastric Cancer, Esophageal Cancer, Small Cell Lung Cancer and Others)
4.3 China PD-1 and PD-L1 Inhibitors Market: Cancer Analysis
4.3.1 China Non-small Cell Lung Cancer (NSCLC) Market by Value
4.3.2 China Non-small Cell Lung Cancer (NSCLC) Market by Treatment (1L Treatment and 2L+ Treatment)
4.3.3 China 1L and 2L+ Non-small Cell Lung Cancer (NSCLC) Treatment Market by Value
4.3.4 China Small Cell Lung Cancer (SCLC) Market by Value
4.3.5 China Small Cell Lung Cancer (SCLC) Market by Treatment (1L Treatment and 2L+ Treatment)
4.3.6 China 1L and 2L+ Small Cell Lung Cancer (SCLC) Treatment Market by Value
4.3.7 China Hepatocellular Carcinoma (HCC) Market by Value
4.3.8 China Hepatocellular Carcinoma (HCC) Market by Treatment (1L Treatment and 2L+ Treatment)
4.3.9 China 1L and 2L+ Hepatocellular Carcinoma (HCC) Treatment Market by Value
4.3.10 China Gastric Cancer (GC) Market by Value
4.3.11 China Gastric Cancer (GC) Market by Treatment (1L Treatment and 2L+ Treatment)
4.3.12 China 1L and 2L+ Gastric Cancer (GC) Treatment Market by Value
4.3.13 China Esophageal Squamous Cell Carcinoma (ESCC) Market by Value
4.3.14 China Esophageal Squamous Cell Carcinoma (ESCC) Market by Treatment (1L Treatment and 2L+ Treatment)
4.3.15 China 1L and 2L+ Esophageal Squamous Cell Carcinoma (ESCC) Treatment Market by Value
4.3.16 China Other Cancers Market by Value
4.3.17 China Other Cancers Market by Treatment (1L Treatment and 2L+ Treatment)
4.3.18 China 1L and 2L+ Other Cancers Treatment Market by Value
4.4 The US PD-1 and PD-L1 Inhibitors Market: An Analysis
4.4.1 The US PD-1 and PD-L1 Inhibitors Market by Value
4.5 ROW PD-1 and PD-L1 Inhibitors Market: An Analysis
4.5.1 ROW PD-1 and PD-L1 Inhibitors Market by Value

5. Market Dynamics
5.1 Growth Driver
5.1.1 Aging Population
5.1.2 Increasing GNI Per Capita
5.1.3 Growing Urban Population
5.1.4 Increased Incidence of Certain Types of Cancer
5.1.5 Surge in the Number of People with Cancer by Age
5.2 Challenges
5.2.1 High Cost of Oncology Treatment
5.2.2 Side Effects and Toxicity
5.2.3 Failure of Clinical Trial
5.2.4 Time Consuming and Uncertain Regulatory Process
5.3 Market Trends
5.3.1 Rising Healthcare Awareness and Changing Lifestyle
5.3.2 Public Medical Insurance
5.3.3 Accelerated Approval of New PD-1 and PD-L1 Inhibitors
5.3.4 Increased Consumption of Alcohol and Smoking

6. Competitive Landscape
6.1 Global PD-1 and PD-L1 Inhibitors Market: Competitive Landscape
6.2 Global PD-1 and PD-L1 Inhibitors Market Players by Phase 3 Studies
6.3 Regulatory Status of Key PD-L1 Drugs in China

7. Company Profiles
7.1 Bristol-Myers Squibb
7.1.1 Business Overview
7.1.2 Financial Overview
7.1.3 Business Strategy
7.2 Merck & Co., Inc.
7.2.1 Business Overview
7.2.2 Financial Overview
7.2.3 Business Strategy
7.3 Roche
7.3.1 Business Overview
7.3.2 Financial Overview
7.3.3 Business Strategy
7.4 AstraZeneca
7.4.1 Business Overview
7.4.2 Financial Overview
7.4.3 Business Strategy
7.5 Jiangsu Hengrui Medicine Co. Ltd.
7.6 BeiGene, Ltd.

List of Tables

Table 1: PD-1/PD-L1 Inhibitors Mechanism Action and Applications
Table 2: Approved PD-1 and PD-L1 inhibitors Timeline; 2017
Table 3: Global PD-1 and PD-L1 Inhibitors Market: Competitive Landscape
Table 4: Regulatory Status of Key PD-L1 Drugs in China

List of Figures

1: PD-1 and PD-L1 Inhibitors Discovery Timeline
Figure 2: PD-1/PD-L1 Inhibitors in Experimental Phase of Development
Figure 3: Adverse Effects of PD-1 and PD-L1 Inhibitors
Figure 4: PD-1 and PD-L1 Inhibitors by Type
Figure 5: PD-1 and PD-L1 Inhibitors by Indications
Figure 6: PD-1 and PD-L1 Inhibitors by Drug
Figure 7: PD-1 and PD-L1 Inhibitors by Distribution Channel
Figure 8: Global PD-1 and PD-L1 Inhibitors Market by Value; 2016-2017 (US$ Billion)
Figure 9: Global PD-1 and PD-L1 Inhibitors Market by Value; 2018-2022 (US$ Billion)
Figure 10: Global PD-1 and PD-L1 Inhibitors Market by Segments; 2017 (Percentage, %)
Figure 11: Global PD-1 and PD-L1 Inhibitors Market by Region; 2017-2018 (Percentage, %)
Figure 12: Global Metastatic PD-1 and PD-L1 Inhibitors Market by Value; 2016-2017 (US$ Billion)
Figure 13: Global Metastatic PD-1 and PD-L1 Inhibitors Market by Value; 2018-2022 (US$ Billion)
Figure 14: Global Adjuvant PD-1 and PD-L1 Inhibitors Market by Value; 2017-2022 (US$ Billion)
Figure 15: China PD-1 and PD-L1 Inhibitors Market by Value; 2018-2022 (US$ Billion)
Figure 16: China PD-1 and PD-L1 Inhibitors Market by Cancer; 2018 & 2022 (Percentage, %)
Figure 17: China PD-1 and PD-L1 Inhibitors Market by Treatment; 2018 (Percentage, %)
Figure 18: China 1L PD-1 and PD-L1 Inhibitors Market by Value; 2018-2022 (US$ Billion)
Figure 19: China 1L PD-1 and PD-L1 Inhibitors Market by Cancer; 2018 (Percentage, %)
Figure 20: China 2L+ PD-1 and PD-L1 Inhibitors Market by Value; 2018-2022 (US$ Million)
Figure 21: China 2L+ PD-1 and PD-L1 Inhibitors Market by Cancer; 2018 (Percentage, %)
Figure 22: China Non-small Cell Lung Cancer (NSCLC) Market by Value; 2018-2022 (US$ Billion)
Figure 23: China Non-small Cell Lung Cancer (NSCLC) Market by Treatment; 2018 (Percentage, %)
Figure 24: China 1L Non-small Cell Lung Cancer (NSCLC) Treatment Market by Value; 2018-2022 US$ Billion)
Figure 25: China 2L+ Non-small Cell Lung Cancer (NSCLC) Treatment Market by Value; 2018-2022 (US$ Million)
Figure 26: China Small Cell Lung Cancer (SCLC) Market by Value; 2018-2022 (US$ Million)
Figure 27: China Small Cell Lung Cancer (SCLC) Market by Treatment; 2018 (Percentage, %)
Figure 28: China 1L Small Cell Lung Cancer (SCLC) Treatment Market by Value; 2018-2022 (US$ Million)
Figure 29: China 2L+ Small Cell Lung Cancer (SCLC) Treatment Market by Value; 2018-2022 (US$ Million)
Figure 30: China Hepatocellular Carcinoma (HCC) Market by Value; 2018-2022 (US$ Million)
Figure 31: China Hepatocellular Carcinoma (HCC) Market by Treatment; 2018 (Percentage, %)
Figure 32: China 1L Hepatocellular Carcinoma (HCC) Treatment Market by Value; 2018-2022 (US$ Million)
Figure 33: China 2L+ Hepatocellular Carcinoma (HCC) Treatment Market by Value; 2018-2022 (US$ Million)
Figure 34: China Gastric Cancer (GC) Market by Value; 2018-2022 (US$ Million)
Figure 35: China Gastric Cancer (GC) Market by Treatment; 2018 (Percentage, %)
Figure 36: China 1L Gastric Cancer (GC) Treatment Market by Value; 2018-2022 (US$ Million)
Figure 37: China 2L+ Gastric Cancer (GC) Treatment Market by Value; 2018-2022 (US$ Million)
Figure 38: China Esophageal Squamous Cell Carcinoma (ESCC) Market by Value; 2018-2022 (US$ Million)
Figure 39: China Esophageal Squamous Cell Carcinoma (ESCC) Market by Treatment; 2018 (Percentage, %)
Figure 40: China 1L Esophageal Squamous Cell Carcinoma (ESCC) Treatment Market by Value; 2018-2022 (US$ Million)
Figure 41: China 2L+ Esophageal Squamous Cell Carcinoma (ESCC) Treatment Market by Value; 2018-2022 (US$ Million)
Figure 42: China Other Cancers Market by Value; 2018-2022 (US$ Million)
Figure 43: China Other Cancers Market by Treatment; 2018 (Percentage, %)
Figure 44: China 1L Other Cancers Treatment Market by Value; 2018-2022 (US$ Million)
Figure 45: China 2L+ Other Cancers Treatment Market by Value; 2018-2022 (US$ Million)
Figure 46: The US PD-1 and PD-L1 Inhibitors Market by Value; 2016-2017 (US$ Billion)
Figure 47: The US PD-1 and PD-L1 Inhibitors Market by Value; 2018-2022 (US$ Billion)
Figure 48: ROW PD-1 and PD-L1 Inhibitors Market by Value; 2016-2017 (US$ Billion)
Figure 49: ROW PD-1 and PD-L1 Inhibitors Market by Value; 2018-2022 (US$ Billion)
Figure 50: World Aging Population by Gender ; 2011-2017 (Trillion)
Figure 51: Global GNI Per Capita; 2010-2016 (US$)
Figure 52: Global Urban Population; 2011-2017 (Billion)
Figure 53: Incidence of Certain Types of Cancer; 2017
Figure 54: Number of People with Cancer by Age; 2011-2016 (Million)
Figure 55: Global Oncology Treatment Cost; 2012-2016 (US$ Billion)
Figure 56: Global PD-1 and PD-L1 Inhibitors Market Players by Phase 3 Studies; 2017 (Percentage, %)
Figure 57: Bristol-Myers Squibb Total Revenue; 2013-2017 (US$ Billion)
Figure 58: Bristol-Myers Squibb Total Revenue by Products; 2017 (Percentage, %)
Figure 59: Bristol-Myers Squibb Total Revenue by Region; 2017 (Percentage, %)
Figure 60: Merck & Co. Inc. Sales; 2013-2017 (US$ Billion)
Figure 61: Merck & Co. Inc. Sales by Segment; 2017 (Percentage, %)
Figure 62: Merck & Co. Inc. Sales by Region; 2017 (Percentage, %)
Figure 63: Roche Sales; 2013-2017 (US$ Billion)
Figure 64: Roche Sales by Segments; 2017 (Percentage,%)
Figure 65: Roche Sales by Region; 2017 (Percentage, %)
Figure 66: AstraZeneca Total Revenue; 2013-2017 (US$ Billion)
Figure 67: AstraZeneca Total Revenue by Region; 2017 (Percentage, %)

  • Global Myelodysplastic Syndrome Market Insights, Forecast to 2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 128
    Myelodysplastic syndromes (MDS) are a group of cancers in which immature blood cells in the bone marrow do not mature and therefore do not become healthy blood cells.[2] Early on there are typically no symptoms.Later symptoms may include feeling tired, shortness of breath, easy bleeding, or frequent infections.[2] Some types may develop into acute myeloid leukemia. The presence of diagnostic tools is the key driver for the growth of this market. Diagnosis techniques like blood count, peri......
  • Global Myasthenia Gravis Drugs Market Insights, Forecast to 2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 120
    Acetylcholine esterase (AChE) inhibitors are considered to be the basic treatment of myasthenia gravis (MG). Edrophonium is primarily used as a diagnostic tool owing to its short half-life. Pyridostigmine is used for long-term maintenance. The market is witnessing the rapid development of novel drugs such as monoclonal antibodies, which is one of the primary factors driving this market's growth prospects. Most drug manufacturers are increasingly focussing on the development of monoclonal ......
  • Global MRSA Drugs Market Insights, Forecast to 2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 122
    Staphylococcus aureus is a bacteria commonly found on nose or skin of healthy people. MRSA i.e., methicillin-resistant staphylococcus aureus, is thus a type of staphylococcus aureus that is resistant to beta-lactam antibiotic called methicillin. MRSA strains do not respond to methicillin treatment. Around 1% of the population carrying staphylococcus aureus on their nose or skin are infected by MRSA. The infection causes skin and tissue infection, and is transmitted by direct skin-to-skin contact......
  • Global Fibrin Sealants Market Insights, Forecast to 2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 125
    Fibrin sealant, a two-component substance consisting of thrombin and fibrinogen, is used as a hemostatic or adhesive in various surgical solutions. In clinical practice, a fibrin sealant consists of a concentrated solution of fibrinogen and Factor XIII, which combine with a solution of calcium and thrombin to form a coagulum that stimulates clotting. Beriplast P and TISSEEL are some of the commercially available fibrin sealants. The Americas accounted for 48% of the market share during th......
  • Global Female Contraceptive Market Insights, Forecast to 2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 110
    Female contraceptives, also known as female birth control are methods of preventing pregnancy that primarily involve the female physiology. Female contraceptive devices account for major shares of the contraceptive pills market throughout the forecast period. The increasing adoption of female contraceptive devices will drive the growth of this product segment in the female contraceptive market. The Americas will be the major revenue contributor to the contraceptive pills market thr......
  • Global Female Condoms Market Insights, Forecast to 2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 114
    A female condom is a birth control device that acts as a barrier to prevent sexual fluids from entering the vagina during intercourse. It protects against pregnancy and sexually transmitted infections (STIs). The online stores will be the fastest-growing segment and will continue to maintain its lead in the global market. Much of the segment's growth is due to its higher penetration rate and adoptability. Female condoms are easily accessible online and allow for useful comparison in terms......
  • Global Excipients Market Insights, Forecast to 2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 111
    Excipients are inert substances that are generally used to manufacture different forms of drugs and are present in the finished products. Excipients help in providing long-term stability and make solid formulations bulkier. They also improve the functionality of drugs and make them safer. Based on functionality, the pharmaceutical excipients market is segmented into fillers & diluents, binders, suspending & viscosity agents, flavoring agents & sweeteners, coating agents, colorants, disint......
  • Global Consumer Healthcare Market Insights, Forecast to 2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 127
    Consumer healthcare products include trusted brands of multivitamins and iron supplements, in addition to products for allergies, personal hygiene, sleep support, alertness and cold and flu. Consumer health products do not require a written prescription from healthcare professionals but can be purchased directly from a pharmacy store. The global Consumer Healthcare market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx%......
  • Global Intravenous (IV) Ibuprofen Market Insights, Forecast to 2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 114
    Intravenous (IV) ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) used to reduce or treat pain, fever, and inflammation occurred due to a disease, operative procedures or trauma, and acute illness. The global Intravenous (IV) Ibuprofen market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Intravenous (IV) Ibuprofen ma......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs